Trial Profile

Neoadjuvant and adjuvant RIBOciclib and endocrine therapy for cLinicAlly high-RISk estrogen receptor-positive (ER+) and HER2-negative (HER2-) breast cancer (RIBOLARIS)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ribociclib (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Letrozole; Paclitaxel
Indications Carcinoma; Early breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms RIBOLARIS

Most Recent Events

14 May 2026 Status changed from recruiting to active, no longer recruiting.
04 Feb 2025 Planned End Date changed from 1 Jul 2030 to 1 Dec 2031.
04 Feb 2025 Planned primary completion date changed from 1 Aug 2028 to 1 Oct 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com